Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Philips Medical Launches New Stethoscopes
November 19, 2001
- Japanese Global Strategy Update (7)
November 19, 2001
- Regulations Related to Medical Devices to Be Reviewed
November 19, 2001
- Takeda: 7.7% Sales Increase Attributable to Int'l Strategic Products
November 19, 2001
- Terumo: Sales Up 7.3%, Profits Down
November 19, 2001
- Santen: Independent Marketing in US Pushes Up Sales
November 19, 2001
- Iressa Effective against NSCLC: PII Results in Int'l Joint Trial
November 19, 2001
- Makers Rush to Apply for Anthrax as Additional Indication
November 19, 2001
- Takeda to Set Up Facility for Gene, Protein Function Analysis
November 19, 2001
- Mitsubishi Research Institute Launches Coding Software Based on Ethical GL
November 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 19, 2001
- BUSINESS NEWS IN BRIEF
November 19, 2001
- Greencross-coa: Sales Up 21% to \23.4 Bil.
November 19, 2001
- OBITUARY
November 19, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 19, 2001
- Industry Fights Price Cuts of Original Products: Chuikyo
November 19, 2001
- Cawachi: Half-year Ordinary Profits Remarkably Up 17.8%
November 19, 2001
- 3 NCEs Including Remicade Recommended to Be Approved
November 19, 2001
- Consumers Take Health-Oriented Foods for Better Nutritional Balance: JMARI Survey
November 19, 2001
- BULLETIN
November 19, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…